stella
beta
SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy Failure — Stella
Recruiting
Back to Gastric Cancer (GC) trials
Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.
Trial locations
(1 site)
China
Liaoning Provincial Cancer Hospital, Shenyang, Liaoning
View full record on ClinicalTrials.gov